Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | MAP3K7 | O43318 | 5/20 | 0.33 |
| ▸ | TAB1 | Q15750 | 5/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.32 |
| ▸ | CDK2 | P24941 | 7/20 | 0.32 |
| ▸ | CCNE2 | O96020 | 6/20 | 0.32 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 3/20 | 0.31 |
| ▸ | CCND1 | P24385 | 3/20 | 0.31 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.31 |
| ▸ | PLK1 | P53350 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2658302 | 1.00 | ADORA2A (0.33) | ADORA2AADORA1MAP3K7TAB1CCNE1 | |
| SCHEMBL10154355 | 0.90 | CDK2 (0.34) | ADORA2AADORA1MAP3K7TAB1CCNE1 | |
| SCHEMBL2658203 | 0.90 | PLK1 (0.36) | ADORA2AADORA1CCNE1CDK2CCNE2 | |
| SCHEMBL2658201 | 0.90 | PLK1 (0.36) | ADORA2AADORA1CCNE1CDK2CCNE2 | |
| SCHEMBL1238734 | 0.90 | ADORA2A (0.35) | ADORA2AADORA1CCNE1CDK2CCNE2 | |
| SCHEMBL2657326 | 0.89 | CDK2 (0.36) | ADORA2AADORA1CCNE1CDK2CCNE2 | |
| SCHEMBL2657324 | 0.89 | CDK2 (0.36) | ADORA2AADORA1CCNE1CDK2CCNE2 | |
| SCHEMBL1240556 | 0.88 | ADORA2A (0.35) | ADORA2AADORA1CCNE1CDK2CCNE2 | |
| SCHEMBL2659010 | 0.87 | CCNE1 (0.41) | ADORA2AADORA1CCNE1CDK2CCNE2 | |
| SCHEMBL2659007 | 0.87 | CCNE1 (0.41) | ADORA2AADORA1CCNE1CDK2CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041711-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2010-02-18 | — | — | US | claimed |
| US-8362049-B2 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2013-01-29 | — | — | US | disclosed |
| US-8362049-B2 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2013-01-29 | — | — | US | disclosed |
| US-8318778-B2 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2012-11-27 | — | — | US | disclosed |
| US-8318778-B2 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2012-11-27 | — | — | US | disclosed |
| US-20120165375-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2012-06-28 | — | — | US | disclosed |
| US-20120165375-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2012-06-28 | — | — | US | disclosed |
| US-20100041711-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2010-02-18 | — | — | US | disclosed |
| US-20100041711-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2010-02-18 | — | — | US | disclosed |
| US-20100041711-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2010-02-18 | — | — | US | disclosed |
| EP-2099777-A1 | UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008084044-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008084044-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041711-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | ADORA2A 1163/4885ADORA1 2103/4885MAP3K7 183/4885 |
| US-20120165375-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | ADORA2A 1163/4885ADORA1 2103/4885MAP3K7 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.